New China Approvals Include Amgen, Sanofi, Hengrui Drugs, Innovent Biosimilar
Executive Summary
Several high-profile products including Dupixent gain approvals in China.
You may also be interested in...
Sanofi Showcases Long-Term Benefits Of Dupixent For Severe Asthma
While many analysts have been focusing on the growth potential of Regeneron-partnered Dupixent in atopic dermatitis, the French giant has been highlighting the biologic's benefits for asthma with three-year data presented at the ERS meeting.
No Looking Back For Sanofi In R&D Turnaround Quest
Sanofi's R&D operation has shaken the dust of diabetes off its feet with an update on its ambitious pipeline plans at an R&D day event.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.